While Big Pharma companies have announced $270 billion in domestic investments, lab leasing declined significantly in Q1 2025, finds JLL’s U.S. Life Sciences Property Report.
A PDUFA decision is expected by June 28. The company is seeking approval of oxylanthanum carbonate for hyperphosphatemia in chronic kidney disease patients on dialysis.
The teaming combines AI-powered protein manufacturing with advanced drug delivery technologies aimed at accelerating timelines and improving therapeutic outcomes.
